"Microfluidic vessels-on-chips for vascular disease modelling" DOI
Heleen Middelkamp

Опубликована: Июнь 22, 2023

Chapter 1General introduction endothelial cell damage 27,29,47,57 .When modelling or inflammatory responses, standard read-outs are fluorescent staining of markers.However, this does not show the functional differences in blood vessel such as monocyte adhesion and thrombus formation which will make them more physiologically relevant can assist assessing patient specific responses.Furthermore, demand for standardized quantifiable is rising 58 .Some BVoC models with perfusion assays already existence [59][60][61][62][63][64] , however standardization, quantification read-outs, systematically setting up co-cultures these needs to be optimized, making measurements translatable comparable 58,[65][66][67] .Current often use fluorescently labelled markers an end-point microscopic measurement 62,68,69 .Thrombus development BVoCs difficult observe real time using assays, furthermore, images give a 2D view thrombus.Therefore non-invasive method measuring clot over time, multiple dimensions, addition understanding clotting mechanisms 70,71 .Many challenges remain creating models, vascular disease modelling, include types possibility read-outs.This thesis aims contribute field by presenting new chip designs, methods co-culturing cells, quantifyable read-outs. Thesis outlineThis presents research towards modelling.Using different designs types, we ability create several vessel-on-chip (VoC) and/or organs read-outs.Chapter 2 consists two parts.The first part describes importance early involvement stakeholders OoCs.It shows stakeholder opinions, overcome process.The next summarizes VoC currently used.Next that discuss possibilities vivo vitro where VoCs still lacking.

Язык: Английский

Emerging trends in organ-on-a-chip systems for drug screening DOI Creative Commons
Yanping Wang, Yanfeng Gao, Yongchun Pan

и другие.

Acta Pharmaceutica Sinica B, Год журнала: 2023, Номер 13(6), С. 2483 - 2509

Опубликована: Фев. 15, 2023

New drug discovery is under growing pressure to satisfy the demand from a wide range of domains, especially pharmaceutical industry and healthcare services. Assessment efficacy safety prior human clinical trials crucial part development, which deserves greater emphasis reduce cost time in discovery. Recent advances microfabrication tissue engineering have given rise organ-on-a-chip, an

Язык: Английский

Процитировано

60
Revolutionizing drug development: harnessing the potential of organ-on-chip technology for disease modeling and drug discovery DOI Creative Commons

Naina Sunildutt,

Pratibha Parihar,

Abdul Rahim Chethikkattuveli Salih

и другие.

Frontiers in Pharmacology, Год журнала: 2023, Номер 14

Опубликована: Апрель 25, 2023

The inefficiency of existing animal models to precisely predict human pharmacological effects is the root reason for drug development failure. Microphysiological system/organ-on-a-chip technology (organ-on-a-chip platform) a microfluidic device cultured with living cells under specific organ shear stress which can faithfully replicate organ-body level pathophysiology. This emerging organ-on-chip platform be remarkable alternative broad range purposes in testing and precision medicine. Here, we review parameters employed using on chip as plot mimic diseases, genetic disorders, toxicity different organs, biomarker identification, discoveries. Additionally, address current challenges that should overcome accepted by regulatory agencies pharmaceutical industries. Moreover, highlight future direction enhancing accelerating discoveries personalized

Язык: Английский

Процитировано

33
Organ-On-A-Chip: An Emerging Research Platform DOI Creative Commons

R Nithin,

Ayushi Aggarwal,

Anne Boyina Sravani

и другие.

Organogenesis, Год журнала: 2023, Номер 19(1)

Опубликована: Ноя. 15, 2023

In drug development, conventional preclinical and clinical testing stages rely on cell cultures animal experiments, but these methods may fall short of fully representing human biology. To overcome this limitation, the emergence organ-on-a-chip (OOC) technology has sparked interest as a transformative approach in research. By closely replicating organ responses to external signals, OOC devices hold immense potential revolutionizing efficacy safety predictions. This review focuses advancements, applications, prospects testing. Based latest advances field systems their reflects effectiveness replacing volunteers certain studies. underscores critical role transforming methodologies.

Язык: Английский

Процитировано

24
Liver-on-chips for drug discovery and development DOI Creative Commons
Viraj Mehta,

Guruswamy Karnam,

Vamsi Madgula

и другие.

Materials Today Bio, Год журнала: 2024, Номер 27, С. 101143 - 101143

Опубликована: Июль 2, 2024

Recent FDA modernization act 2.0 has led to increasing industrial R&D investment in advanced

Язык: Английский

Процитировано

11
Organoid, organ-on-a-chip and traditional Chinese medicine DOI Creative Commons
Jiayue Yang, Yu Jiang, Mingxing Li

и другие.

Chinese Medicine, Год журнала: 2025, Номер 20(1)

Опубликована: Фев. 12, 2025

Abstract In the past few years, emergence of organoids and organ-on-a-chip (OOAC) technologies, which are complementary to animal models two-dimensional cell culture methods can better simulate internal environment human body, provides a new platform for traditional Chinese medicine (TCM) studies. Organoids OOAC techniques have been increasingly applied in fields drug screening, assessment development, personalized therapies, developmental biology, there some application cases TCM this review, we summarized current status using organoid technologies research provide key insights future study. It is believed that will play more important roles make greater contributions innovative development TCM.

Язык: Английский

Процитировано

1
In Vitro Modeling of Interorgan Crosstalk: Multi-Organ-on-a-Chip for Studying Cardiovascular-Kidney-Metabolic Syndrome DOI
Cody Juguilon, Ramak Khosravi, Milica Radisic

и другие.

Circulation Research, Год журнала: 2025, Номер 136(11), С. 1476 - 1493

Опубликована: Май 22, 2025

Cardiovascular-kidney-metabolic syndrome is a progressive disorder driven by perturbed interorgan crosstalk among adipose, liver, kidney, and heart, leading to multiorgan dysfunction. Capturing the complexity of human cardiovascular-kidney-metabolic pathophysiology using conventional models has been challenging. Multi-organ-on-a-chip platforms offer versatile means study underlying signaling at different stages bolster clinical translation.

Язык: Английский

Процитировано

1
Advances in Human Organs-on-Chips and Applications for Drug Screening and Personalized Medicine DOI Creative Commons
Chenyang Zhou, Zhangjie Li, Kangyi Lu

и другие.

Fundamental Research, Год журнала: 2024, Номер unknown

Опубликована: Фев. 1, 2024

The limitations of conventional animal tests and two-dimensional cell culture hinder their advancement in fundamental research clinical/translational applications. As an emerging alternative technology, organ-on-a-chip serves as a platform that faithfully simulates the key phenotypical, physiological, functional features human tissues/organs through accurate regulation parameters such physical biochemical microenvironment, well cellular patterns. In this review, we mainly introduce recent progress field, including lung, gut, heart, liver, vasculature multiorgan studies. Furthermore, highlight potential applications drug screening personalized medicine. Finally, conclude by addressing current challenges future perspective technology commercialization organ-on-chips. We anticipate development will revolutionize studies on biology medicine providing new understanding mechanisms diseases insights into clinical therapeutics.

Язык: Английский

Процитировано

6
3D Humanized Bioprinted Tubulointerstitium Model to Emulate Renal Fibrosis In Vitro DOI Creative Commons
Gabriele Addario, Julia Fernández‐Pérez, Chiara Formica

и другие.

Advanced Healthcare Materials, Год журнала: 2024, Номер 13(29)

Опубликована: Авг. 17, 2024

Abstract Chronic kidney disease (CKD) leads to a gradual loss of function, with fibrosis as pathological endpoint, which is characterized by extracellular matrix (ECM) deposition and remodeling. Traditionally, in vivo models are used study interstitial fibrosis, through histological characterization biopsy tissue. However, ethical considerations the 3Rs (replacement, reduction, refinement) regulations emphasizes need for humanized 3D vitro models. This introduces bioprinted model combines primary human cells decellularized partially digested (ddECM). A protocol was established decellularize pig tissue ddECM encapsulate renal cells. To investigate progression, were treated transforming growth factor beta 1 (TGF‐β1), mechanical properties hydrogel modulated using vitamin B2 crosslinking. The bioprinting perfusable replicates tubulointerstitium. Results show an increased Young's modulus over time, together increase ECM components cell dedifferentiation toward myofibroblasts. Multiple fibrotic genes resulted upregulated, closely resembled terms collagen deposition. offers more physiologically relevant platform studying potentially improving progression research high‐throughput drug screening.

Язык: Английский

Процитировано

5
Organ‐On‐a‐Chip devices: Technology Progress and Challenges DOI
Pierre J. Obeid, Paolo Yammine,

Hanna El‐Nakat

и другие.

ChemBioChem, Год журнала: 2024, Номер 25(23)

Опубликована: Авг. 26, 2024

Abstract Organ‐On‐a‐Chip (OOC) is a multichannel 3D‐microfluidic cell‐culture system incorporated in chip that simulates the behavior of an organ. This technology relies on multidisciplinary science benefits from and contributes progress many fields including microbiology, microfluidics, biomaterials, bioengineering. review article summarizes achievements various organ‐on‐chip technologies. It highlights significant advantages this terms reducing animal testing providing personalized medical responses. In addition, paper demonstrates how OOC becoming promising powerful tool pharmaceutical research to combat diseases. predicts not only effects drugs target organs but also, using body‐on‐a‐chip systems, it may provide insights into side drug delivery other organs. Likewise, models used for construction organ‐on‐a‐chip devices are investigated along with design materials microfluidic devices. For each OOC, integrated monitoring within chips (e. g., sensors biosensors) discussed. We also discuss evolution FDA regulations potential near future integrating OOCs protocols support reduce need failure rates preclinical clinical studies.

Язык: Английский

Процитировано

4
Kidney Fibrosis In Vitro and In Vivo Models: Path Toward Physiologically Relevant Humanized Models DOI Creative Commons
Gabriele Addario, Lorenzo Moroni, Carlos Mota

и другие.

Advanced Healthcare Materials, Год журнала: 2025, Номер unknown

Опубликована: Фев. 5, 2025

Abstract Chronic kidney disease (CKD) affects over 10% of the global population and is a leading cause mortality. Kidney fibrosis, key endpoint CKD, disrupts nephron tubule anatomy filtration function, pathomechanisms are not fully understood. fibrosis currently investigated with in vivo models, that gradually support identification possible mechanisms but limited translational research, as they do recapitulate human physiology, metabolism, molecular pathways. In vitro 2D cell culture models used, starting point modeling pharmacology, however, lack 3D architecture complexity functions. The failure several therapies drugs clinical trials highlights urgent need for advanced models. This review discusses urinary system's anatomy, associated diseases, diagnostic methods, including biomarker analysis tissue biopsy. It evaluates highlighting their limitations. explores state‐of‐the‐art 3D‐humanized such aggregates, on‐chip biofabrication techniques, hybrid which aim to mimic morphogenesis These hold promise translating new into clinics.

Язык: Английский

Процитировано

0